EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Predicting amyloid‐beta pathology in the general population

Phuong Thuy Nguyen Ho, Joyce van Arendonk, Rebecca M E Steketee, Frank J A van Rooij, Gennady V Roshchupkin, M Arfan Ikram, Meike W Vernooij, Julia Neitzel iD

Alzheimer's & Dementia · 2023-12 · 19 (12) · 5506-5517

DOI: 10.1002/alz.13161 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 11.06.2023. Verfasst von Phuong Thuy Nguyen Ho und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Centre, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Alzheimer Disease. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ZonMw, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Reliable models to predict amyloid beta (Aβ) positivity in the general aging population are lacking but could become cost‐efficient tools to identify individuals at risk of developing Alzheimer's disease. METHODS We developed Aβ prediction models in the clinical Anti‐Amyloid Treatment in Asymptomatic Alzheimer's (A4) Study ( n = 4,119) including a broad range of easily ascertainable predictors (demographics, cognition and daily functioning, health and lifestyle factors). Importantly, we determined the generalizability of our models in the population‐based Rotterdam Study ( n = 500). RESULTS The best performing model in the A4 Study (area under the curve [AUC] = 0.73 [0.69–0.76]), including age, apolipoprotein E ( APOE ) ε4 genotype, family history of dementia, and subjective and objective measures of cognition, walking duration and sleep behavior, was validated in the independent Rotterdam Study with higher accuracy (AUC = 0.85 [0.81–0.89]). Yet, the improvement relative to a model including only age and APOE ε4 was marginal. DISCUSSION Aβ prediction models including inexpensive and non‐invasive measures were successfully applied to a general population–derived sample more representative of typical older non‐demented adults.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid beta-PeptidesAlzheimer DiseaseAdultHumansAgedApolipoprotein E4CognitionAmyloid

Stichwörter der Autor:innen

Alzheimer's diseaseamyloid-beta pathologydementiamachine learningprediction models

Substanzen

Amyloid beta-PeptidesApolipoprotein E4Amyloid

Autor:innen und Institutionen

  • Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Centre, Rotterdam, the Netherlands.
  • Department of Epidemiology, Erasmus MC, University Medical Centre, Rotterdam, the Netherlands.
  • Department of Epidemiology, Harvard T.H Chan School of Public Health, Boston, Massachusetts, USA.

ORCID-Profile: Julia Neitzel

Förderung

  • ZonMw
  • NIA NIH HHS

Zitieren

APA

Nguyen Ho, P. T., van Arendonk, J., Steketee, R. M. E., van Rooij, F. J. A., Roshchupkin, G. V., Ikram, M. A., Vernooij, M. W., & Neitzel, J. (2023). Predicting amyloid‐beta pathology in the general population. Alzheimer's & Dementia, 19(12), 5506-5517. https://doi.org/10.1002/alz.13161

Vancouver

Nguyen Ho PT, van Arendonk J, Steketee RME, van Rooij FJA, Roshchupkin GV, Ikram MA, et al. Predicting amyloid‐beta pathology in the general population. Alzheimer's & Dementia. 2023;19(12):5506-5517. doi:10.1002/alz.13161

BibTeX
@article{NguyenHo2023,
  author = {Nguyen Ho, Phuong Thuy and van Arendonk, Joyce and Steketee, Rebecca M E and van Rooij, Frank J A and Roshchupkin, Gennady V and Ikram, M Arfan and Vernooij, Meike W and Neitzel, Julia},
  title = {Predicting amyloid‐beta pathology in the general population},
  journal = {Alzheimer's & Dementia},
  year = {2023},
  volume = {19},
  number = {12},
  pages = {5506--5517},
  doi = {10.1002/alz.13161}
}
Kostenlos starten →